Bio-Techne Corp
A maker of the proteins, antibodies, and lab instruments that scientists use to study cells and diagnose disease, Bio-Techne sells brands like R&D Systems and ProteinSimple to researchers worldwide. It began in 1976 in Minneapolis as R&D Systems, making controls to verify blood-analysis machines, and rebranded as Bio-Techne in 2014 — a name blending "bio" with the Greek word "techne," meaning art or craft. Its first product, launched in 1977, was a platelet-rich-plasma control.
Granted 124.0K
Granted 74.5K
Granted 10.7K
Granted 1.4K
Granted 6.6K · Sold 6.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Hippel JamesCFO · 4 transactions | +7.7% | 153.7K | 124.0K | — | — |
| Kelderman KimChief Executive Officer, Director · 6 transactions | +84.4% | 89.8K | 74.5K | — | — |
| Bohnen ShaneSVP - General Counsel · 4 transactions | +47.6% | 7.2K | 10.7K | — | — |
| Crouse Steven C.President - Diag & Spatial Bi · 4 transactions | — | 6.8K | 1.4K | — | — |
| Herr Amy E.Director · 2 transactions | 0% | 2.9K | 6.6K | — | 6.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -6.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.